Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q4 2013 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$148.45K$148.45Kderived+110.1% vs Q4 2012 Net Income$111.69K$111.69KderivedN/M vs Q4 2012 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$46,240+26.7% Operating Incomederived-$103,058N/M Operating Cash Flowderived$8,468N/M Margins · derivedGross margin31.1%−20.5 pt vs Q4 2012
Operating margin-69.4%+1539.3 pt vs Q4 2012
Net margin75.2%+1683.7 pt vs Q4 2012
ended Dec 31, 2013 · filed Apr 14, 2014 · 104 d after period end